Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TLR4 | O00206 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 2/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2914226 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TLR4TSHRCYP2C9LMNA | |
| SCHEMBL4333449 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TLR4TSHRCYP2C9LMNA | |
| SCHEMBL7901823 | 0.94 | TSHR (0.37) | ALDH1A1TLR4TSHRCYP2C9LMNA | |
| SCHEMBL7901831 | 0.94 | TSHR (0.37) | ALDH1A1TLR4TSHRCYP2C9LMNA | |
| SCHEMBL1894593 | 0.94 | ALDH1A1 (0.43) | ALDH1A1TLR4TSHRCYP2C9LMNA | |
| SCHEMBL2913315 | 0.94 | ALDH1A1 (0.43) | ALDH1A1TLR4TSHRCYP2C9LMNA | |
| SCHEMBL7735949 | 0.88 | TSHR (0.43) | ALDH1A1TLR4TSHRCYP2C9LMNA | |
| SCHEMBL7735946 | 0.88 | TSHR (0.43) | ALDH1A1TLR4TSHRCYP2C9LMNA | |
| SCHEMBL7735940 | 0.88 | TSHR (0.43) | ALDH1A1TLR4TSHRCYP2C9LMNA | |
| SCHEMBL8454463 | 0.88 | ALDH1A1 (0.33) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2020407-B1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | JNC CORP (JP) | 2013-07-03 | — | — | EP | disclosed |
| EP-2020407-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | Chisso Corporation (JP) | 2009-02-04 | — | — | EP | disclosed |
| US-6458433-B1 | ISOTOPE REPLACEMENT; OPTICAL DISPLAY | CHISSO CORPORATION (JP) | 2002-10-01 | — | — | US | disclosed |
| US-20020038858-A1 | Isotope replacement; optical display | JNC CORPORATION (JP) | 2002-04-04 | — | — | US | disclosed |
| US-6174459-B1 | HAVING BUTYLENE GROUP AND/OR A PROPYLENEOXY GROUP AND A 3,4-DIFLUOROPHENYL GROUP AND WHICH CAN EXPRESS SOME PHYSICAL PROPERTIES SUITABLE AS A LIQUID CRYSTAL DISPLAY MATERIAL | CHISSO CORPORATION (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0949232-A1 | DIFLUOROPHENYL DERIVATIVES, LIQUID-CRYSTAL COMPOUNDS, AND LIQUID-CRYSTAL COMPOSITION | CHISSO CORPORATION (JP) | 1999-10-13 | — | — | EP | disclosed |
| EP-0922021-A1 | DIFLUOROPHENYL DERIVATIVE COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 1999-06-16 | — | — | EP | disclosed |
| WO-1998007674-A1 | DIFLUOROPHENYL DERIVATIVE COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 1998-02-26 | — | — | WO | disclosed |
| EP-0325796-B1 | A LIQUID CRYSTAL COMPOUND AND A MIXTURE CONTAINING THE SAME | Chisso Corporation (JP) | 1992-03-11 | — | — | EP | disclosed |
| US-4877548-A | STABLE TO HEAT, LIGHT, ELECTRICITY AND MOISTURE | CHISSO CORPORATION (JP) | 1989-10-31 | — | — | US | disclosed |
| EP-0325796-A1 | A liquid crystal compound and a mixture containing the same | Chisso Corporation (JP) | 1989-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038858-A1 | Isotope replacement; optical display | IRS1, FES, IK | ALDH1A1 1909/4885TLR4 2638/4885TSHR 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.